Summary

Patients with type 2 diabetes mellitus (T2DM) who are treated with empagliflozin, a sodium glucose cotransporter 2 inhibitor, as monotherapy or add-on antihyperglycemic therapy experience clinically meaningful improvements in glycemic parameters and several cardiovascular risk factors. This article discusses the results of a pooled analysis of four randomized, placebo-controlled Phase 3 trials in which the effects of 24 weeks of empagliflozin were evaluated in 2477 T2DM patients.